Sumitomo Dainippon Pharma Co Ltd (4506.T)
29 Aug 2014
|Market Cap (Mil.):||¥562,232.88|
|Shares Outstanding (Mil.):||397.90|
TOKYO, March 31 - Takeda Pharmaceutical Co Ltd and Dainippon Sumitomo Pharma Co Ltd said on Monday the European Commission had given them marketing authorisation for Latuda, a once-a-day oral treatment for schizophrenia in adults.
Earnings vs. Estimates
Analyst Research Reports
Sumitomo Dainippon Pharma Co Ltd: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: MarketLine (a Datamonitor Company)
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.